Home/Pipeline/Novel AMD Antibody Therapy

Novel AMD Antibody Therapy

Wet and Dry Age-related Macular Degeneration (AMD)

PreclinicalActive

Key Facts

Indication
Wet and Dry Age-related Macular Degeneration (AMD)
Phase
Preclinical
Status
Active
Company

About maintect

maintect is a private, preclinical-stage biotech based in Mainz, Germany, founded in 2018. The company pursues a dual business model: providing contract research services for lateral flow assay (LFA) and antibody drug development, and driving its own proprietary programs in ophthalmic diagnostics and therapeutics for AMD. Its core strategy leverages expertise in immunochromatography and antibody engineering to address significant unmet needs in both the diagnostics and therapeutics markets for retinal diseases.

View full company profile

Therapeutic Areas